A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC in Adults With Ocular Myasthenia Gravis
Public ClinicalTrials.gov record NCT06558279. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double-Blinded, Placebo-Controlled, Phase 3, Parallel-Group Design Study Evaluating the Efficacy and Safety of Efgartigimod PH20 SC Administered by Prefilled Syringe in Adult Participants With Ocular Myasthenia Gravis
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to evaluate the efficacy and safety of efgartigimod PH20 SC given by a pre-filled syringe in adult patients with ocular myasthenia gravis. The study consists of a part A (approximately 7 weeks) and a part B (up to 2 years). In part A, half of the participants will receive efgartigimod PH20 SC and the other half will receive placebo. In part B, all participants will receive efgartigimod PH20 SC. The participants will be in the study for about up to 2 years and 12 weeks.
Study identification
- NCT ID
- NCT06558279
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 141 participants
Conditions and interventions
Conditions
Interventions
- Efgartigimod PH20 SC Combination Product
- Placebo PH20 SC Other
Combination Product · Other
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 18, 2024 (Actual)
- Primary completion
- Jan 12, 2026 (Actual)
- Completion
- Dec 2027 (Estimated)
- Last update posted
- Jul 2, 2026
2024 – 2027
United States locations
- U.S. sites
- 20
- U.S. states
- 12
- U.S. cities
- 19
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| HonorHealth Neurology - Bob Bové Neuroscience Institute | Scottsdale | Arizona | 85251 | — |
| Loma Linda University Health | Loma Linda | California | 92354 | — |
| USC Roski Eye Institute - Los Angeles | Los Angeles | California | 90033 | — |
| University of California San Francisco | San Francisco | California | 94143 | — |
| Neurology Offices of South Florida | Boca Raton | Florida | 33428-4221 | — |
| SFM Clinical Research, LLC | Boca Raton | Florida | 33487-2768 | — |
| Neurology Associates PA | Maitland | Florida | 32751 | — |
| University of South Florida | Tampa | Florida | 33620 | — |
| Northwestern Memorial Hospital | Chicago | Illinois | 60611 | — |
| University of California Irvine | Columbia | Maryland | 21044 | — |
| Massachusetts General Hospital | Boston | Massachusetts | 02114 | — |
| Henry Ford Health System | Detroit | Michigan | 48202 | — |
| Robert Wood Johnson Medical School | New Brunswick | New Jersey | 08901 | — |
| University of North Carolina at Chapel Hill | Chapel Hill | North Carolina | 27514 | — |
| Duke Neurological Disorders Clinic | Durham | North Carolina | 27710 | — |
| Cleveland Clinic | Cleveland | Ohio | 44195 | — |
| Martha Morehouse Medical plaza | Columbus | Ohio | 43221 | — |
| Penn Medicine University City | Philadelphia | Pennsylvania | 19104 | — |
| National Neuromuscular Research Institute | Austin | Texas | 78759-8402 | — |
| Houston Methodist Neurological Institute | Houston | Texas | 77030 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 82 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06558279, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 2, 2026 · Synced Oct 24, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT06558279 live on ClinicalTrials.gov.